Publication:
Advancements in synthetic biology-based bacterial cancer therapy: A modular design approach.

dc.contributor.authorArboleda-García, Andrés
dc.contributor.authorAlarcón-Ruiz, Iván
dc.contributor.authorBoada-Acosta, Lissette
dc.contributor.authorBoada, Yadira
dc.contributor.authorVignoni, Alejandro
dc.contributor.authorJantus-Lewintre, Eloisa
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERONC (Cáncer)es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.date.accessioned2024-02-09T15:39:15Z
dc.date.available2024-02-09T15:39:15Z
dc.date.issued2023-10
dc.description.abstractSynthetic biology aims to program living bacteria cells with artificial genetic circuits for user-defined functions, transforming them into powerful tools with numerous applications in various fields, including oncology. Cancer treatments have serious side effects on patients due to the systemic action of the drugs involved. To address this, new systems that provide localized antitumoral action while minimizing damage to healthy tissues are required. Bacteria, often considered pathogenic agents, have been used as cancer treatments since the early 20th century. Advances in genetic engineering, synthetic biology, microbiology, and oncology have improved bacterial therapies, making them safer and more effective. Here we propose six modules for a successful synthetic biology-based bacterial cancer therapy, the modules include Payload, Release, Tumor-targeting, Biocontainment, Memory, and Genetic Circuit Stability Module. These will ensure antitumor activity, safety for the environment and patient, prevent bacterial colonization, maintain cell stability, and prevent loss or defunctionalization of the genetic circuit.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis research was funded by MCIN/AEI/10.13039/501100011033 Grant numbers PID2020-117271RB-C21 and TED2021-131049B-I00, Generalitat Valenciana GVA Grant CIAICO/2021/159, Centro de Investigacion ´ Biom´edica en Red de Cancer ´ (CIBERONC) Grant CB16-12- 00350, Instituto de Salud Carlos III (Grant PI22/01221), and GVA Grant AICO/2021/333. A Arboleda-García thanks the Grant PAID-01–21 Programa de Ayudas de Investigacion ´ y Desarrollo from Universitat Polit`ecnica de Val`encia, Spain. I Alarcon-Ruiz thanks the FPU grant (FPU20/04814) from the Spanish Government. L Boada-Acosta thanks the Grant Santiago Grisolía GRISOLIAP/2021/030 from Conselleria de Innovacion, ´ Universidades, Ciencia y Sociedad Digital and Generalitat Valenciana, Spain. Y Boada is thankful for the Grant PAID-10-21 Acceso al Sistema Espanol ˜ de Ciencia e Innovacion ´ from Universitat Polit`ecnica de Val`encia, Spain; and the Scholarship Convocatoria Abierta 2011 from Secretaría de Educacion ´ Superior, Ciencia, Tecnología e Innovacion, ´ Ecuador. The authors are grateful to Prof. Jesús Pico ´ for his guidance during the preparation of this manuscript. BioRender was used to illustrate the figures under a paid license for publication authorization.es_ES
dc.format.page104088es_ES
dc.format.volume190es_ES
dc.identifier.citationCrit Rev Oncol Hematol. 2023 Oct:190:104088.es_ES
dc.identifier.doi10.1016/j.critrevonc.2023.104088es_ES
dc.identifier.e-issn1879-0461es_ES
dc.identifier.journalCritical reviews in oncology/hematologyes_ES
dc.identifier.pubmedID37541537es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17710
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2020-117271RB-C21es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/TED2021-131049B-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CIAICO/2021/159es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU20/04814es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/GRISOLIAP/2021/030es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PAID-10-21es_ES
dc.relation.publisherversion10.1016/j.critrevonc.2023.104088es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Genética Funcional del Sistema de Fosforilación Oxidativaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshSynthetic Biologyes_ES
dc.subject.meshNeoplasmses_ES
dc.subject.meshHumanses_ES
dc.subject.meshGenetic Engineeringes_ES
dc.subject.meshBacteriaes_ES
dc.subject.meshGene Regulatory Networkses_ES
dc.titleAdvancements in synthetic biology-based bacterial cancer therapy: A modular design approach.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Advancements in synthetic_Crit Rev Oncol Hematol_2023.pdf
Size:
5.59 MB
Format:
Adobe Portable Document Format
Description:
Artículo